Frequencies of small, large, twin and total mosaic spots in <i>D</i>.<i>melanogaster</i> wings of individuals treated with Chios mastic oil (CMO), mitomycin-C (MMC) (2.5 <i>μ</i>g/ml) or their mixture.

<p>¹The number of mutant spots is given in parenthesis. Symbols next to values signify the following: +, positive mutagenic effect;-, no mutagenic effect; i, inconclusive effect (p = 0.05); Statistical diagnosis according to Frei & Würgler [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0130498#pone.0130498.ref038" target="_blank">38</a>].</p><p>Frequencies of small, large, twin and total mosaic spots in <i>D</i>.<i>melanogaster</i> wings of individuals treated with Chios mastic oil (CMO), mitomycin-C (MMC) (2.5 <i>μ</i>g/ml) or their mixture.</p

Comparative distribution of MN frequency (‰) induced by CMW, MMC and their combination.

<p>The dotted line is read on the left hand Y-axis and the solid line on the right hand Y-axis.</p

Frequencies of BNMN and MN as well as CBPI values in cultured human lymphocytes treated with CMW, MMC (0.05 and 0.50 µg/ml) and their mixture.

<p>BN: binucleated cells; BNMN: micronucleated binucleated cells; MN: micronuclei; CBPI: Cytokinesis Block Proliferation Index; CMW: Chios Mastic Water; MMC: Mitomycin-C; MF (‰) ± se, mean frequencies (‰) ± standard error; MN were scored in 2000 binucleated lymphocytes per experimental point;</p>1,2,3<p>significant difference in relation to control at <i>p</i><0.05, <i>p</i><0.01 and <i>p</i><0.001 respectively;</p>a,b,c<p>significant difference in relation to MMC at <i>p</i><0.05, <i>p</i><0.01 and <i>p</i><0.001 respectively [G-test for BNMN and MN; <i>χ2</i> for CBPI].</p

Frequencies of micronucleated binucleated cells (BNMN) and micronuclei (MN) as well as cytokinesis block proliferation index (CBPI) values in cultured human lymphocytes which have been treated with Chios mastic oil (CMO), mitomycin-C (MMC) (0.05 <i>μ</i>g/ml) and their mixture.

<p>BN: binucleated cells; BNMN: micronucleated binucleated cells; MN: micronuclei; CBPI: Cytokinesis Block Proliferation Index; CMO: Chios Mastic Oil; MMC: Mitomycin-C; MF (‰)±se, mean frequencies (‰)±standard error; MN were scored in 2000 binucleated lymphocytes per experimental point;</p><p>¹ Significant difference compared to control at p<0.001;</p><p>^a Significant difference compared to MMC at p<0.001; G-test for BNMN and MN; <i>χ</i>^<i>2</i> for CBPI</p><p>Frequencies of micronucleated binucleated cells (BNMN) and micronuclei (MN) as well as cytokinesis block proliferation index (CBPI) values in cultured human lymphocytes which have been treated with Chios mastic oil (CMO), mitomycin-C (MMC) (0.05 <i>μ</i>g/ml) and their mixture.</p

Summary of the results obtained in the Somatic Mutation And Recombination Test (SMART) on <i>Drosophila melanogaster,</i> after larvae treatment with CMW, MMC (1.00, 2.50 and 5.00 µg/ml) and their mixture.

<p>Symbols next to values signify the following: +, positive mutagenic effect; −, no mutagenic effect; w, weakly positive effect; i, inconclusive effect; <i>m</i> is the multiplication factor¹ (<i>p = </i>0.05); ^{a, b, c} is significant difference in relation to MMC at <i>p</i><0.05, <i>p</i><0.01 and <i>p</i><0.001, respectively (U-test).</p>1<p>The number of mutant spots is given in parenthesis. Statistical diagnosis according to Frei and Würgler <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069494#pone.0069494-Frei1" target="_blank">[53]</a>.</p

Wing spot frequency (%) induced by MMC (1.00, 2.50 and 5.00 µg/ml) in presence of CMW (50 and 100% v/v).

<p>[*<i>p</i><0.05, **<i>p</i><0.01, ***<i>p</i><0.001, U-test].</p

Reduction (%) of MN frequency induced by MMC (0.05 and 0.50 µg/ml) in presence of CMW (1, 2 and 5% v/v).

<p>Reduction (%) of MN frequency induced by MMC (0.05 and 0.50 µg/ml) in presence of CMW (1, 2 and 5% v/v).</p

Demographic and clinical attendance characteristics of the studied population (n = 204).

<p>^aDuration since diagnosis of CIS or clinically definite MS until study enrollment.</p><p>^bIKA: Social Insurance Institute, OPAD: Insurance institute for employees of the public sector, ΟAEE: Insurance institute for freelancers. One patient had both “other public insurance” and “private insurance”.</p><p>Demographic and clinical attendance characteristics of the studied population (n = 204).</p

Patients' medical attendance, hospitalization and laboratory requirements of the studied population (n = 204).

<p>^aNumber of patients' admissions to hospitals to counteract relapses within the last year. In this category, the visits to one-day clinics are not included.</p><p>^bThis information was missing in 7 patients.</p><p>^cThis information was missing in 2 patients.</p><p>Patients' medical attendance, hospitalization and laboratory requirements of the studied population (n = 204).</p

Health care service use related to visits to neurologists, other doctors and health professionals.

<p>Health care service use related to visits to neurologists, other doctors and health professionals.</p